About Killer cell immunoglobulin-like receptor 2DL1
Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) is a protein
from Homo sapiens identified by UniProt accession
P43626, 348 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Killer cell immunoglobulin-like receptor 2DL1 |
|---|
| UniProt accession | P43626 |
|---|
| Gene | KIR2DL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 348 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (110)
Diseases linked to this target (Open Targets).
- monocyte percentage of leukocytes · score 0.13
- keratoconus · score 0.11
- acute myeloid leukemia · score 0.10
- multiple myeloma · score 0.10
- chronic lymphocytic leukemia · score 0.07
- leukemia · score 0.07
- head and neck squamous cell carcinoma · score 0.07
- breast cancer · score 0.07
- cancer · score 0.06
- esophageal squamous cell carcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43626-F1 | alphafold | PREDICTED | 75.17 | — |
Amino-acid sequence (348 residues)
MSLLVVSMAC VGFFLLQGAW PHEGVHRKPS LLAHPGRLVK SEETVILQCW SDVMFEHFLL HREGMFNDTL RLIGEHHDGV SKANFSISRM TQDLAGTYRC YGSVTHSPYQ VSAPSDPLDI VIIGLYEKPS LSAQLGPTVL AGENVTLSCS SRSSYDMYHL SREGEAHERR LPAGPKVNGT FQADFPLGPA THGGTYRCFG SFHDSPYEWS KSSDPLLVSV TGNPSNSWPS PTEPSSKTGN PRHLHILIGT SVVIILFILL FFLLHRWCSN KKNAAVMDQE SAGNRTANSE DSDEQDPQEV TYTQLNHCVF TQRKITRPSQ RPKTPPTDII VYTELPNAES RSKVVSCP
Explore Killer cell immunoglobulin-like receptor 2DL1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets